Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Frequently asked questions
What sector does Adaptive Biotechnologies Corporation (1HM) operate in?
Adaptive Biotechnologies Corporation belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Adaptive Biotechnologies Corporation (1HM) current stock price?
As of the latest data, Adaptive Biotechnologies Corporation stock price is €23.92, with a previous close of €22.87. Adaptive Biotechnologies Corporation gained €1.05 in the last trading session, representing a 4.59% increase.
What is Adaptive Biotechnologies Corporation (1HM) current market capitalization?
Adaptive Biotechnologies Corporation market cap is approximately 3.82 billion.
What is Adaptive Biotechnologies Corporation (1HM) Earnings Per Share (EPS)?
The trailing EPS is -€0.34.
Does Adaptive Biotechnologies Corporation (1HM) pay dividends?
No. Adaptive Biotechnologies Corporation does not pay a dividend.
When is Adaptive Biotechnologies Corporation (1HM) next earnings report?
Adaptive Biotechnologies Corporation is expected to release its next earnings report on September 30, 2026.
What is Adaptive Biotechnologies Corporation (1HM) beta (volatility) score?
Adaptive Biotechnologies Corporation has a beta of 2.096, indicating very high volatility compared to the market.
